Clinical Trial Update: Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and imaging performance of rhPSMA-7.3 labeled with fluorine-18 in healthy volunteers and patients with prostate cancer; results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• rhPSMA-7.3 (18F) PET tracer (rhPSMA-7.3 radiolabeled PSMA-targeted PET imaging agent)

Snippet

Sponsor: Blue Earth Diagnostics | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2026-02-12